Predictable growth.
On January 5, Tomson Beijian released a performance forecast, and it is expected that the net profit attributable to shareholders of listed companies in 2023 will be about 159.4 billion - 187.1 billion yuan, a year-on-year increase of 15%-35%;Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses142.4 billion - 172.1 billion yuan, a year-on-year increase of 35%-25.1%。
For the performance forecast, Tomson Beijian said in the report that 2023 is the first year of the new cycle of the VDS industry, and the company will continue to promote the transformation of strong technology enterprises and strong brand strategy under the strategy of "scientific nutrition", and further deepen management and improve the quality of operation in accordance with the strategic direction of multi-brand large single products, all categories, and all channels.
However, due to the strong consumer demand for immunity-enhancing products in the fourth quarter of 2022 and the high revenue base, the revenue in the fourth quarter of 2023 decreased slightly compared with the same period last year. In addition, due to the large investment in brand building, the single-quarter sales expense ratio is the highest in the whole year, and the company's performance in the fourth quarter of 2023 is expected to decline compared with the same period last year.
However, the positive full-year results have made the market maintain confidence in Tomson By-Health. According to the research report of China Securities Construction Investment, Tomson Beijian's Q4 declined slightly due to the impact of the base, and the annual performance was in line with expectations. In January 2024, the new phase of the equity incentive of Tomson By-Health was implemented, and the development potential of Tomson By-Health was optimistic about the development potential of Tomson's multi-category, and it continued to lay out the blue ocean track through the large-scale single product model.
In the view of Chinese food industry analysts, the growth of Tomson Beijian is predictable. "In the post-epidemic era, the people are paying more and more attention to weight management, appearance management, health management and nutrition management, which provides a broad market space for the development of Tomson By-Health. With R&D strength, brand influence, scale advantage and rich product matrix, By-Health has a strong competitive advantage. Therefore, we are optimistic about the future development of Tomson By-Health. With the vigorous development of the silver economy, I am more optimistic about the future prospects of Tomson By-Health. ”
Benefit from increased health awareness.
2023 is regarded as the first year of the new cycle of the VDS industry, benefiting from the growth of market demand for multiple categories of products brought about by the improvement of national health awareness, and the revenue of By-Health in 2023 will achieve rapid growth.
Jiang Han, a senior researcher at Pangu Think Tank, analyzed, "According to the performance forecast released by Tomson By-Health, the company has achieved a year-on-year increase in net profit in 2023, which shows that the company has performed well in the past year and has developed its business steadily." From a long-term perspective, this also reflects the strong competitiveness and market position of By-Health in the health care products industry. ”
Combined with the performance of the first three quarters of 2023, from January to September 2023, Tomson Beijian achieved an operating income of 778.2 billion yuan, an increase of 26 over the same period last year34%, net profit attributable to shareholders of listed companies 190.1 billion yuan, a year-on-year increase of 2828%。
According to the previous financial report, in the main business income, the main brand "Tomson Beijian" achieved revenue of 45% in the first three quarters1.1 billion yuan, a year-on-year increase of 3038%；"Lifespace" domestic products achieved revenue of 38.4 billion yuan, a year-on-year increase of 5196%。In terms of overseas business, LSG achieved operating income of 77.4 billion yuan, a year-on-year increase of 3427%。
In addition, during the Double "Eleventh" period, By-Health handed over the report card that the sales of its whole brand and the whole network exceeded 900 million yuan, a year-on-year increase of more than 20%, ranking first in the industry. At the same time, the overall sales of Tomson's professional probiotic brand "Lifespace" reached 15.7 billion yuan, a year-on-year increase of more than 26%, and its Lifespace Australia's **32 billion probiotics were listed on JD.com's "Imported Gastrointestinal Probiotics List" TOP1.
Jiang Han told "Consumption Titanium" that the development trend of the health care products industry is closely related to people's lifestyles and health concepts. With the improvement of people's living standards and the enhancement of health awareness, consumers' demand for health care products is increasing, especially some products with specific functions are widely welcomed. At the same time, with the continuous progress of science and technology, the health care products industry is also gradually realizing science and technology, intelligence, which has brought new opportunities and challenges to the development of the industry.
Embrace the new cycle.
In the view of Tomson Beijian, 2023 may be the best time for a new layout.
In 2023, under the strategy of "scientific nutrition", By-Health will continue to promote the transformation of a strong technology enterprise and the strategy of strengthening brands, lay out multi-brand, large-scale single products, all categories, all channels, and single focus, and focus on the market goal of increasing the designated purchase rate and omni-channel market share to meet the challenges of the new cycle.
Among them, the "scientific nutrition" strategy of By-Health has established a comprehensive scientific system of dietary nutritional supplements, relying on modern nutritional science to create a strong scientific nutritional product force. In addition, By-Health has always adhered to the harsh raw material audit system, with the quality advantage strategy of global raw materials, in the general homogenization of products, the formation of the core competitiveness of quality differentiation, so far the raw materials have been produced in 23 countries and regions around the world.
Jiang Han believes that Tomson Beijian has a competitive advantage in promoting the "scientific nutrition" strategy. "The formation of this advantage is mainly due to Tomson's focus on R&D and innovation, with independent core technology and patented raw materials, and can continue to launch differentiated and competitive productsAt the same time, By-Health has established a comprehensive scientific system of dietary nutritional supplements, relying on modern nutritional science to create a strong scientific nutritional product forceIn addition, By-Health has always adhered to the harsh raw material audit system, and formed the core competitiveness of quality differentiation in the general homogenization of products with the quality advantage strategy of global raw materials. ”
As of the end of June 2023, By-Health has obtained 103 invention patents for raw materials and formulas, and has reached agreements with more than 10 well-known research institutions in Europe and the United States to build a global research resource system.
It is worth mentioning that the strategy of "multi-brand large single product" has helped many of Tomson's products to achieve high sales in their fields, and many sub-categories have ranked on the platform's "hot sale" and "word-of-mouth" lists. It is reported that Tomson Beijian protein powder occupies the TOP1 of Tmall's immunity protein powder category and the TOP1 of JD.com's "Protein Powder Gold List".The professional probiotic brand "lifespace" occupies the top 1 of the Tmall imported probiotics praise list and the top 1 of the JD hot listThe new YEP-GAGS collagen peptide occupies the TOP1 of Tmall's "Collagen V List".Jianli polyaminic chondroitin products have also appeared on the Tmall chondroitin hot list, praise list, and repurchase list.